SLC31A1 and ovarian carcinoma: The clinical relevance of CTR1 expression levels was further demonstrated in ovarian carcinoma patients: elevated expression of CTR1 was associated with enhanced therapeutic responses, while low transporter levels worsened the therapeutic outcome (Lee et al., 2011).